Billy W Loo, Jr, MD PhD FASTRO FACR

Professor of Radiation Oncology (Radiation Therapy)

Bio

Billy W. Loo Jr., MD PhD is a Professor of Radiation Oncology, a member of the Stanford Cancer Institute, of the Molecular Imaging Program at Stanford (MIPS), and of Bio-X. He is a physician-scientist Radiation Oncologist and Bioengineer who directs the Thoracic Radiation Oncology Program and is Principal Investigator of the FLASH Sciences Lab @Stanford.

His clinical specialty is precision targeted radiotherapy for lung/thoracic cancers, including stereotactic ablative radiotherapy (SABR). Dr. Loo is a recognized expert in thoracic cancers serving on multiple national committees (including as writing member or vice-chair) that publish clinical guidelines on the treatment of lung cancer and other thoracic malignancies, particularly the National Comprehensive Cancer Network (NCCN).

His clinical research is in clinical trials and implementation of new treatment techniques for lung cancer, and development of new medical imaging methods for measuring organ function and predicting response to cancer treatment. He also has developed novel applications of SABR including treatment of pulmonary emphysema and cardiac arrhythmias.

Since conceiving of a fundamentally new approach to delivering ultra-rapid, ultra-precise cancer therapy, pluridirectional high-energy agile scanning electronic radiotherapy (PHASER), Dr. Loo's major laboratory research focus has been to co-lead a collaborative effort between Stanford Medicine and SLAC National Accelerator Laboratory to develop PHASER into a transformative and clinically practical technology. This program comprises both technology development and fundamental research on the radiobiology of extremely rapid FLASH therapy to optimize the biological therapeutic index.

Dr. Loo received his MD from University of California, Davis and his PhD in Bioengineering from University of California, San Francisco and Berkeley. He completed his Radiation Oncology residency training at Stanford University. He is certified by the American Board of Radiology in Radiation Oncology, and is a Fellow of the American Society for Radiation Oncology (ASTRO) and a Fellow of the American College of Radiology (ACR).

Clinical Focus

Cancer > Head and Neck Cancer
Cancer > Radiation Oncology
Cancer > Thoracic Oncology
Lung Cancer
Thoracic Cancers
Stereotactic Ablative Radiotherapy (SABR)
Radiation Oncology
Radiation Therapy

Academic Appointments

Professor - University Medical Line, Radiation Oncology - Radiation Therapy
Member, Bio-X
Member, Maternal & Child Health Research Institute (MCHRI)
Member, Stanford Cancer Institute
Member, Wu Tsai Neurosciences Institute

Administrative Appointments

Director of Thoracic Radiation Oncology, Radiation Oncology (2005 - Present)
Director of New Technologies, Radiation Oncology (2011 - Present)
Director of VA Radiation Oncology Services, Radiation Oncology (2019 - Present)

Honors & Awards

Fellow of the American College of Radiology (FACR), ACR (2022)
Fellow of the American Society for Radiation Oncology (FASTRO), ASTRO (2021)
Henry S. Kaplan Memorial Prize for Teaching, Stanford University (2021)
StartX Professor in Residence, StartX (2021)
Educator of the Year Award, Association of Residents in Radiation Oncology (2012)
Henry S. Kaplan Memorial Prize for Teaching in Radiation Oncology, Stanford University (2009)
Basic Science Travel Grant, ASTRO (2005)
Young Investigator Travel Grant, ECOG (2005)
Molecular Biology in Clinical Oncology Workshop Scholarship, AACR (2004)
Roentgen Resident/Fellow Research Award, RSNA (2004)
Travel Grant Award, Best of ASCO Meeting, Denver, ASCO (2004)
Malcolm A. Bagshaw Award, Stanford Radiation Oncology (2003)
Graduate Student Research Award, University of California, San Francisco (1996)
Regents Fellowship, University of California (1996)
Laboratory Graduate Fellowship, Associated Western Universities (1994, 1995)
Research Scholarship, California Medical Education and Research Foundation (1992)
Rapp/Rummelsberg Research Scholarship, - (1991)

Boards, Advisory Committees, Professional Organizations

Vice Chair, National Comprehensive Cancer Network Small Cell Lung Cancer Panel (2013 - Present)

Professional Education

Residency: Stanford University Radiation Oncology Residency (2005) CA
Internship, Kaiser Permanente San Francisco Internal Medicine Residency, CA (2001)
Medical Education: University of California Davis School of Medicine (2000) CA
Board Certification: American Board of Radiology, Radiation Oncology (2006)
Ph.D., U.C. San Francisco, U.C. Berkeley, Bioengineering (2000)
A.B., U.C. Berkeley, Biophysics (1989)

Patents

R. Fahrig, B.W. Loo, P.G. Maxim, S. Tantawi. "United States Patent 10,806,950 B2 Arrays of accelerating structures and rapid imaging for facilitating rapid radiation therapies", The Board of Trustees of the Leland Stanford Junior University, Oct 20, 2020
V. Bharadwaj, V.A. Dolgashev, R. Fahrig, B.W. Loo, P.G. Maxim, S. Tantawi, C. Limborg, L. Nicolas. "United States Patent 10,576,303 B2 Methods and systems for beam intensity-modulation to facilitate rapid radiation therapies", The Board of Trustees of the Leland Stanford Junior University, Mar 3, 2020
B.W. Loo, P.G. Maxim, V.A. Dolgashev. "Sweden Patent EP2823501B1 Pluridirectional very high electron energy radiation therapy systems", Leland Stanford Junior University, May 1, 2019
R. Fahrig, B.W. Loo, P.G. Maxim, S. Tantawi. "United States Patent 9,962,562 B2 Arrays of accelerating structures and rapid imaging for facilitating rapid radiation therapies", The Board of Trustees of the Leland Stanford Junior University, May 8, 2018
V. Bharadwaj, V.A. Dolgashev, R. Fahrig, B.W. Loo, P.G. Maxim, S. Tantawi, C. Limborg, L. Nicolas. "United States Patent 9,931,522 B2 Methods and systems for beam intensity-modulation to facilitate rapid radiation therapies", The Board of Trustees of the Leland Stanford Junior University, Apr 3, 2018
B.W. Loo, P.G. Maxim, V.A. Dolgashev. "China P.Rep. Patent CN104246961B Pluridirectional very high electron energy radiation therapy systems and processes", Leland Stanford Junior University, May 17, 2017
B.W. Loo, P.G. Maxim, V.A. Dolgashev. "United States Patent 9,018,603 B2 Pluridirectional very high electron energy radiation therapy systems and processes", The Board of Trustees of the Leland Stanford Junior University, Apr 28, 2015
P.J. Keall, A. Sawant, P.G. Maxim, Y. Suh, L. Xing, B.W. Loo Jr., B.C. Cho. "United States Patent 8,849,373 B2 Method and apparatus for real-time target position estimation by combining x-ray and external respiratory signals", Stanford University, Sep 30, 2014
B.W. Loo Jr., P.G. Maxim, V.A. Dolgashev. "United States Patent 8,618,521 B2 Pluridirectional very high electron energy radiation therapy systems and processes", The Board of Trustees of the Leland Stanford Junior University, Dec 31, 2013
E. Johnston, B.W. Loo Jr., P.G. Maxim, M. Diehn. "United States Patent 8,526,702 B2 4D anatomically based image selection procedure for medical imaging", The Board of Trustees of the Leland Stanford Junior University, Sep 3, 2013

Contact

Academic Tel: (650) 736-7143 Fax: (650) 725-8231

Administrative Contact Kevin Flores Assistant Clinical Research Coordinator kevinflo@stanford.edu Tel: 650-725-4796

Clinical (Primary)

This is the primary clinic for this clinical provider. For additional clinical locations and information, please visit the link(s) listed below in the 'Additional Clinical Info' section.

Stanford Dept Of Radiation Oncology 875 Blake Wilbur Dr MC 5847 Stanford CA 94305 Tel: (650) 736-7143 Fax: (650) 723-3913

Additional Clinical Info

Current Research and Scholarly Interests

As Director of Thoracic Radiation Oncology, my clinical specialty is precision targeted radiotherapy of lung and other thoracic cancers.

My clinical research focus is on clinical trials and clinical translation of advanced high-precision 4-D image-guided radiation therapy and stereotactic ablative radiotherapy (SABR), as well as novel indications of SABR such as severe pulmonary emphysema. I also conduct preclinical and translational research in novel functional and metabolic imaging and imaging biomarkers.

I am Principal Investigator of the FLASH Sciences Lab @Stanford, specializing in preclinical research on the biology, physics, and engineering of ultra-rapid FLASH radiotherapy. I also co-lead a collaboration between the Department of Radiation Oncology and SLAC National Accelerator Laboratory to develop a next-generation ultra-rapid and precise medical linear accelerator technology (PHASER).

Clinical Trials

Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if giving radiation therapy to the head is effective in preventing CNS metastases in patients who have stage III non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying how well radiation therapy to the head works in preventing CNS metastases in patients who have been previously treated for stage III non-small cell lung cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Derek Huang, 6507250203.
Lead Sponsor
Stanford Investigators
View full details
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Not Recruiting
More
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. This may be an effective treatment for extensive stage small cell lung cancer. PURPOSE: This randomized phase II trial is comparing how well radiation therapy to the brain works when given with or without radiation therapy to other areas of the body in treating patients with extensive stage small cell lung cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Laura Gable, 6507360798.
Lead Sponsor
Stanford Investigators
View full details
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers Recruiting
More
The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Endoscopic Capillary Oximetry for Tumor Diagnosis in Head and Neck Cancer Not Recruiting
More
Endoscopy is a standard part of the evaluation of patients with head and neck cancer used for determining the extent of tumor involvement. However, not all areas involved by tumor are apparent visually. Preliminary results indicate that compared with normal tissues, tumors have abnormal levels of capillary oxygenation. The purpose of this study is to determine the ability of non-pulsatile visible light tissue oxygen monitoring to differentiate normal and tumor tissue based on capillary oxygenation during endoscopy Should this be possible, this method could be used to mark tumor extent and invasion, even when that invasion is up to 5mm blow the tissue surface.

Stanford is currently not accepting patients for this trial. For more information, please contact Peter Maxim, 6507243018.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy Not Recruiting
More
This study assesses computed tomography (CT) perfusion imaging in predicting treatment response in patients with non-small cell lung cancer or tumors that have spread from the primary site (place where it started) to the lungs (metastases) treated with stereotactic ablative radiation therapy. CT perfusion imaging is a special type of CT that uses an injected dye in order to see how blood flow through tissues, including lung tissue. CT perfusion imaging of the lungs may help doctors learn whether perfusion characteristics of lung tumors may be predictive of response to treatment and whether lung perfusion characteristics can be used to follow response to treatment.

Stanford is currently not accepting patients for this trial. For more information, please contact Samantha Wong, 650-498-8495.

Lead Sponsor
- Stanford University
Stanford Investigators
- Maximilian Diehn, MD, PhD
- Billy W Loo, Jr, MD PhD FASTRO FACR
View full details
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy Recruiting
More
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Evaluation of Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Cancer Not Recruiting
More
This study has two primary objectives. The first objective is to determine the maximal tolerated dose (MTD) that can be delivered with stereotactic radiosurgery in patients with inoperable malignant lung tumors. Once the MTD is established, the second objective is to determine the efficacy of radiosurgical ablation of lung tumors in terms of symptoms and radiographic responses.

Stanford is currently not accepting patients for this trial. For more information, please contact Lisa Zhou, 6507364112.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy Not Recruiting
More
To develop and investigate a novel radiotherapy technique for preserving lung function based on a map of lung function.

Stanford is currently not accepting patients for this trial. For more information, please contact Laura Gable, 650-736-0798.
Lead Sponsor
Stanford Investigators
View full details
Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation Not Recruiting
More
The purpose of this study is to determine the value of novel non-invasive medical imaging methods for detecting the spread of head and neck squamous cell carcinoma to the lymph nodes in the neck by comparing their results to findings at the time of surgery.

Stanford is currently not accepting patients for this trial. For more information, please contact Quynh-Thu Le, 6504986184.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy Not Recruiting
More
This phase II trial studies how well radical-dose image guided radiation therapy works in treating patients with non-small cell lung cancer that has spread to other places in the body who are undergoing immunotherapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radical-dose image guided radiation therapy to patients with non-small cell lung cancer may help to improve response to immunotherapy anti-cancer treatment.

Stanford is currently not accepting patients for this trial. For more information, please contact Kim Nguyen, 650-497-8966.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Indirect Magnetic Resonance Lymphangiography of the Head and Neck Region Using Conventional Gadolinium-based Contrast Not Recruiting
More
To determine the ability of magnetic resonance lymphangiography using conventional gadolinium injected directly into the tumor site and PET scan in detecting microscopic nodal metastasis in patients with newly diagnosed H\&N cancers

Stanford is currently not accepting patients for this trial. For more information, please contact Bill Loo, 6507367143.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Not Recruiting
More
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vaccine therapy together with bevacizumab after chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects of giving BLP25 liposome vaccine together with bevacizumab after chemotherapy and radiation therapy in treating patients with newly diagnosed stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery.

Stanford is currently not accepting patients for this trial. For more information, please contact Maria Pitsiouni, 650-721-6977.
Lead Sponsor
Stanford Investigators
View full details
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel, carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether high-dose radiation therapy is more effective than standard-dose radiation therapy when given together with combination chemotherapy with or without cetuximab in treating patients with non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying high-dose or standard-dose radiation therapy given together with chemotherapy with or without cetuximab to see how well they work in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery.

Stanford is currently not accepting patients for this trial. For more information, please contact Laura Gable, 6507360798.
Lead Sponsor
Stanford Investigators
- Billy W Loo, Jr, MD PhD FASTRO FACR
View full details
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer Not Recruiting
More
The purpose of this study is to assess the short and long-term outcomes after CyberKnife stereotactic radiosurgery for early stage non-small cell lung cancer (NSCLC) in patients who are medically inoperable.

Stanford is currently not accepting patients for this trial. For more information, please contact Lisa Zhou, 6507364112.
Lead Sponsor
Stanford Investigators
View full details
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer Not Recruiting
More
RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy and radiation therapy. It is not yet known whether Manuka honey is more effective than standard care in preventing pain. PURPOSE: This randomized phase II clinical trial is studying Manuka honey to see how well it works in preventing esophagitis-related pain in patients receiving chemotherapy and radiation therapy for lung cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Laura Gable, 6507360798.
Lead Sponsor
Stanford Investigators
View full details
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Not Recruiting
More
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Katie Brown, 650-723-1423.
Lead Sponsor
Stanford Investigators
View full details
Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer Not Recruiting
More
RATIONALE: Surgery with or without internal radiation therapy may be an effective treatment for non-small cell lung cancer. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. It is not yet known whether stereotactic body radiation therapy is more effective than surgery with or without internal radiation therapy in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying how well surgery with or without internal radiation therapy works compared with stereotactic body radiation therapy in treating patients with high-risk stage IA or stage IB non-small cell lung cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Lisa Zhou, 6507364112.
Lead Sponsor
Stanford Investigators
View full details
Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status Not Recruiting
More
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of specialized radiation therapy in treating patients with stage II, stage III, stage IV, or recurrent non-small cell lung cancer and poor performance status.

Stanford is currently not accepting patients for this trial. For more information, please contact Laura Gable, 6507360798.
Lead Sponsor
Stanford Investigators
- Billy W Loo, Jr, MD PhD FASTRO FACR
View full details
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer Not Recruiting
More
Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been a standard of care for operable early stage NSCLC. Several studies have reported high local control and survival using SBRT in stage I NSCLC patients. SBRT is now an accepted treatment for medically inoperable patients with stage I NSCLC and patients with operable stage I lung cancer are entered on clinical protocols. The purpose of this study is to conduct a phase III randomized study to compare CyberKnife SBRT with surgery, the current standard of care for stage I operable NSCLC.

Stanford is currently not accepting patients for this trial. For more information, please contact Lisa Zhou, 6507364112.
Lead Sponsor
Stanford Investigators
View full details
Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC Not Recruiting
More
The purpose of this study is to assess how well this particular combination of chemotherapy, radiation and surgery works to help people with locally advanced lung cancer, how well PET scans indicates whether someone has responded to chemotherapy and radiation, and gene expression patterns related to outcomes in patients with locally advanced lung cancer who receive this treatment regimen.

Stanford is currently not accepting patients for this trial. For more information, please contact Lisa Zhou, 6507364112.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Pulmonary Interstitial Lymphography in Early Stage Lung Cancer Not Recruiting
More
The stereotactic body radiation therapy (SBRT) procedure is an emerging alternative to the standard treatment for early stage non-small cell lung cancer (NSCLC), typically lobectomy with lymphadenectomy. This procedure (lobectomy) does not fulfill the medical need as many patients are poor operative candidates or decline surgery. This study assesses the feasibility of stereotactic body radiation therapy (SBRT) as a tool to produce therapeutically useful computed tomography (CT) scans, using standard water-soluble iodinated compounds as the contrast agents.

Stanford is currently not accepting patients for this trial. For more information, please contact Laura Gable, 6507360798.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
The Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging Not Recruiting
More
This study will investigate whether audiovisual biofeedback, in which visual and audio cues are used to regulate the patient's breathing, can increase the image quality of 4D CT and 4D PET scans.

Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .

Lead Sponsor
- Stanford University
Stanford Investigators
- Billy W Loo, Jr, MD PhD FASTRO FACR
View full details
Molecular Analysis of Thoracic Malignancies Not Recruiting
More
A research study to learn about the biologic features of cancer development, growth, and spread. We are studying components of blood, tumor tissue, normal tissue, and other fluids, such as urine, cerebrospinal fluid, abdominal or chest fluid in patients with cancer. Our analyses of blood, tissue, and/or fluids may lead to improved diagnosis and treatment of cancer by the identification of markers that predict clinical outcome, markers that predict response to specific therapies, and the identification of targets for new therapies.

Stanford is currently not accepting patients for this trial. For more information, please contact Jordan Preiss, 650-723-1002.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer Not Recruiting
More
This randomized phase II trial studies how well positron emission tomography (PET)/computed tomography (CT)-guided radiation therapy works compared to standard radiation therapy in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Using imaging procedures, such as PET and CT scans, to guide the radiation therapy, may help doctors deliver higher doses directly to the tumor and cause less damage to healthy tissue.

Stanford is currently not accepting patients for this trial. For more information, please contact Laura Gable, 650-736-0798.
Lead Sponsor
Stanford Investigators
View full details
Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known which regimen of stereotactic body radiation therapy is more effective in treating patients with non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying the side effects of two radiation therapy regimens and to see how well they work in treating patients with stage I non-small cell lung cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact laura gable, 6507360798.
Lead Sponsor
Stanford Investigators
View full details
SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer Not Recruiting
More
The SABR-ATAC trial (Stereotactic Ablative Radiotherapy and anti-TGFB Antibody Combination) is a phase I/II trial that studies the side effects and efficacy of fresolimumab, an anti-transforming growth factor beta (TGFB) antibody, when given with stereotactic ablative radiotherapy in patients with stage IA-IB non-small cell lung cancer. Fresolimumab may inhibit radiation side effects and block tumor growth through multiple mechanisms. Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiotherapy (SBRT), is a specialized form of radiation therapy that precisely delivers high dose radiation directly to tumors, thus killing tumor cells and minimizing damage to normal tissue. Giving fresolimumab with SABR may work better in treating patients with early stage non-small cell lung cancer than treating with SABR alone.

Stanford is currently not accepting patients for this trial. For more information, please contact Laura Gable, 650-736-0798.
Lead Sponsor
Stanford Investigators
View full details
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Not Recruiting
More
This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, etoposide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving erlotinib hydrochloride is more effective than crizotinib with chemoradiation therapy in treating patients with non-small cell lung cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Katie Brown, 650-723-1423.
Lead Sponsor
Stanford Investigators
View full details
Imaging and Biomarkers of Hypoxia in Solid Tumors Not Recruiting
More
Hypoxia, meaning a lack of oxygen, has been associated strongly with a wide range of human cancers. Hypoxia occurs when tumor growth exceeds the ability of blood vessels to supply the tumor with oxygenated blood. It is currently understood that hypoxic tumors are more aggressive. Current methods for measuring hypoxia include invasive procedures such as tissue biopsy, or insertion of an electrode into the tumor. EF5-PET may be a non-invasive way to measure tumor hypoxia.

Stanford is currently not accepting patients for this trial. For more information, please contact Justin Carter, 650-725-4796.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors Not Recruiting
More
This study aims to investigate and optimize imaging sequences and parameters of rapid real-time MRI in order to obtain adequate guidance for accurately and precisely delivering radiation to moving abdominal and thoracic tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact Melody Chung, 6507360798.

Lead Sponsor
- Stanford University
Stanford Investigators
- Shreyas Vasanawala, MD/PhD
- Billy W Loo, Jr, MD PhD FASTRO FACR
View full details
The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers Not Recruiting
More
In patients with cancer of the head and neck and rectum, knowing the exact location of the tumor is important for designing the radiation field to ensure delivery of high dose of radiation to the tumor while sparing surrounding normal tissues. A new medical imaging method which is a combination of positron emission tomography (PET) and computed tomography (CT) scan, has shown promise in helping the radiation oncologist in defining the exact location and extent of the tumor in certain cancers such as lung cancers. Therefore the purpose of this study is to determine if these imaging methods can be used in combination with the standard radiation treatment planning procedure to improve the accuracy to targeting your tumor with radiation. In addition the PET-CT scan, similar to the PET scan alone with better resolution, can be used to determine whether the tumor has spread to any part of the body outside of the head and neck sites.

Stanford is currently not accepting patients for this trial. For more information, please contact Quynh-Thu Le, 6504986184.

Lead Sponsor
- Stanford University
Stanford Investigators
- Quynh-Thu Le, MD
- Billy W Loo, Jr, MD PhD FASTRO FACR
View full details
Breath Analysis for Evaluation of Radiation Exposure in Lung Cancer Patients Treated With Radiation Not Recruiting
More
Patients treated with radiation therapy for lung tumors can experience inflammation after treatment. This study hopes to evaluate the use of breath analysis to evaluate changes in the composition of exhaled breath in patients undergoing radiotherapy. If changes can be detected, this may ultimately serve as biomarkers for identifying patients at highest risk for radiation-induced lung injury (radiation pneumonitis).

Stanford is currently not accepting patients for this trial. For more information, please contact Laura Gable, 6507360798.

Lead Sponsor
- Stanford University
Stanford Investigators
- Maximilian Diehn, MD, PhD
- Billy W Loo, Jr, MD PhD FASTRO FACR
View full details
Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers Not Recruiting
More
The purpose of this study is to study the effect of the drug DCA (dichloroacetate) on recurrent head and neck cancers. Part of this study will also use EF5 PET scan to study tumor hypoxia.

Stanford is currently not accepting patients for this trial. For more information, please contact Alice Banh, 650-723-1423.
Lead Sponsor
Stanford Investigators
View full details
Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) Not Recruiting
More
A research study of a procedure to treating lung cancer with focused radiation called Stereotactic Ablative Radiotherapy (SABR). The purpose of this study is to evaluate the effectiveness of individualizing the dose of radiation used to treat lung tumors with SABR based on tumor-specific factors. While recent research has identified SABR as a promising method to increase local control (LC) of lung cancer, further research has indicated that tumor volume is a prognostic factor, with increased size/volume of tumor being associated with poorer outcomes. This study explores if a volume-adapted strategy for the radiologic exposure (dose) will improve efficacy in larger tumors (ie, \> 10 cc). This is a study of the procedure stereotactic ablative radiotherapy (SABR). It is not a study of a specific drug or device.

Stanford is currently not accepting patients for this trial. For more information, please contact Samantha Wong, 650-498-8495.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations Not Recruiting
More
1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients with nasopharyngeal carcinoma (NPC). 2. To relate pretreatment plasma EBV DNA concentration to WHO classification of these tumors both in endemic and non-endemic areas. 3. To determine whether pretreatment plasma EBV DNA can serve as a prognostic factor for both endemic and non-endemic patient populations.

Stanford is currently not accepting patients for this trial. For more information, please contact Quynh-Thu Le, 650-498-6184.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery Not Recruiting
More
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue near the tumor. PURPOSE: This phase II trial is studying how well stereotactic body radiation therapy works in treating patients with stage I or stage II non-small cell lung cancer that can be removed by surgery.

Stanford is currently not accepting patients for this trial. For more information, please contact Melody Chung, 6507360798.
Lead Sponsor
Stanford Investigators
- Billy W Loo, Jr, MD PhD FASTRO FACR
View full details
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Not Recruiting
More
RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving these treatments before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether chemotherapy and radiation therapy are more effective when given with or without panitumumab in treating patients with non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying chemotherapy and radiation therapy to see how well they work when given with or without panitumumab in treating patients with stage IIIA non-small cell lung cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Laura Gable, 6507360798.
Lead Sponsor
Stanford Investigators
View full details

2024-25 Courses

Independent Studies
- Directed Reading in Radiation Oncology
  RADO 299 (Aut, Win, Spr)
- Early Clinical Experience in Radiation Oncology
  RADO 280 (Aut, Win, Spr)
- Graduate Research
  RADO 399 (Aut, Win, Spr)
- Medical Scholars Research
  RADO 370 (Aut, Win, Spr)
- Readings in Radiation Biology
  RADO 101 (Aut, Win, Spr)
- Undergraduate Research
  RADO 199 (Aut, Win, Spr)

Stanford Advisees

Postdoctoral Faculty Sponsor
Nikita Katila, Vivek Jaysukhlal Maradia, Luis Soto

Billy W Loo, Jr, MD PhD FASTRO FACR

Professor of Radiation Oncology (Radiation Therapy)

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators